High doses of aminoglycosides did not produce liver toxicity in patients with cystic fibrosis.

[1]  B. Strandvik,et al.  Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. , 2008, Liver.

[2]  B. Strandvik,et al.  Bile‐duct destruction and collagen deposition: A prominent ultrastructural feature of the liver in cystic fibrosis , 1992, Hepatology.

[3]  L. Leibovici,et al.  Prospective Evaluation of Liver Function Tests in Patients Treated with Aminoglycosides , 1990, DICP : the annals of pharmacotherapy.

[4]  B. Strandvik.  Antibiotic therapy of pulmonary infections in cystic fibrosis. Dosage schedules and duration of treatment. , 1988, Chest.

[5]  K. Gaskin,et al.  Liver disease and common-bile-duct stenosis in cystic fibrosis. , 1988, The New England journal of medicine.

[6]  B. Strandvik,et al.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis , 1987, Journal of clinical microbiology.

[7]  B. Strandvik,et al.  Morphological findings in the liver of children with cystic fibrosis: A light and electron microscopical study , 1986, Hepatology.

[8]  A. Keshavarzian,et al.  Production of peptides inducing chemotaxis and lysosomal enzyme release in human neutrophils by intestinal bacteria in vitro and in vivo. , 1986, Scandinavian journal of gastroenterology.

[9]  R. Moore,et al.  Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. , 1986, The American journal of medicine.

[10]  B. Strandvik,et al.  Fasting serum bile acid levels in relation to liver histopathology in cystic fibrosis. , 1985, Scandinavian journal of gastroenterology.

[11]  G. Laurent,et al.  Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. , 1984, Kidney international.

[12]  B. Strandvik,et al.  Relation between Antibody Response to Pseudomonas aeruginosa Exoproteins and Colonization/Infection in Patients with Cystic Fibrosis , 1984, Acta paediatrica Scandinavica.

[13]  P. Tulkens,et al.  Early effects of gentamicin, tobramycin, and amikacin on the human kidney. , 1984, Kidney international.

[14]  B. Strandvik,et al.  Prospective Study of Fatty Acid Supplementation Over 3 Years in Patients with Cystic Fibrosis , 1983, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[15]  G. Lepage,et al.  Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. , 1982, Journal of pediatric gastroenterology and nutrition.

[16]  Isenberg Jn.  Cystic Fibrosis: Its Influence on the Liver, Biliary Tree, and Bile Salt Metabolism , 1982, Seminars in liver disease.

[17]  N. HØiby,et al.  ANTIMICROBIAL CHEMOTHERAPY IN CYSTIC FIBROSIS PATIENTS , 1982 .

[18]  P. Lietman,et al.  Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C. , 1982, The Journal of pharmacology and experimental therapeutics.

[19]  P. Tulkens,et al.  Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[20]  T. Boat,et al.  Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic hunting. , 1976, Gastroenterology.

[21]  O. Pavlovskis,et al.  Pseudomonas aeruginosa exotoxin in mice: histopathology and serum enzyme changes. , 1976, The Journal of infectious diseases.

[22]  J. Kattwinkel,et al.  The effects of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis. , 1973, The Journal of pediatrics.

[23]  E. Weibel,et al.  PRACTICAL STEREOLOGICAL METHODS FOR MORPHOMETRIC CYTOLOGY , 1966, The Journal of cell biology.

[24]  H. Shwachman,et al.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. , 1958, A.M.A. journal of diseases of children.

[25]  B. Strandvik,et al.  Sclerosing cholangitis in cystic fibrosis. , 1988, Scandinavian journal of gastroenterology. Supplement.

[26]  R. Moore,et al.  Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. , 1984, The Journal of infectious diseases.

[27]  B. Strandvik,et al.  Urinary bile acid excretion in correlation to liver histopathology in cystic fibrosis. , 1980, Scandinavian journal of gastroenterology.